Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Europe-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Europe

Published:2017-01 Issue:1 Volume:5 Page:1299665
ISSN:2001-6689
Container-title:Journal of Market Access & Health Policy
language:en
Short-container-title:Journal of Market Access & Health Policy

Author:

Medic Goran¹²,Korchagina Daria³,Young Katherine Eve⁴,Toumi Mondher⁵^ORCID,Postma Maarten Jacobus²^ORCID,Wille Micheline¹,Hemels Michiel¹

Affiliation:

1. Horizon Pharma Europe B.V., Market Access EMEA, AH Utrecht, the Netherlands

2. Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, the Netherlands

3. Mental Health and Public Health, University Paris-Sud, Maison de Solenn, Paris, France

4. Creativ-Ceutical, Paris, France

5. Public Health Department, Research Unit, Aix-Marseille University, Marseille, France

Funder

Horizon Pharma

Publisher

Informa UK Limited

Link

https://tandfonline.com/doi/pdf/10.1080/20016689.2017.1299665

Reference24 articles.

1. Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?

2. Estimating the budget impact of orphan medicines in Europe: 2010 - 2020

3. Pricing and reimbursement of orphan drugs: the need for more transparency

4. Orphan drugs policies: a suitable case for treatment

5. What Is Wrong with Orphan Drug Policies?

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Defining ‘therapeutic value’ of medicines: a scoping review;BMJ Open;2023-12

2. Literature Review on Health Emigration in Rare Diseases—A Machine Learning Perspective;International Journal of Environmental Research and Public Health;2023-01-30

3. Moving beyond the Court of Public Opinion: A Citizens’ Jury Exploring the Public’s Values around Funding Decisions for Ultra-Orphan Drugs;International Journal of Environmental Research and Public Health;2022-12-30

4. Valuation of Treatments for Rare Diseases: A Systematic Literature Review of Societal Preference Studies;Advances in Therapy;2022-12-01

5. The actual status of drug prices and adjustment factors for drug price calculation: an analysis of ultra-orphan drug development in Japan;Orphanet Journal of Rare Diseases;2022-11-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3